The research publication of the iPS cell-derived pancreatic islet cell therapy for type 1 diabetes project in T-CiRA Joint Program were published online in the Diabetes on January 31st 2020.

The research publication of the iPS cell-derived pancreatic islet cell therapy for type 1 diabetes project in T-CiRA Joint Program were published online in the Diabetes on January 31st 2020.

Paper Details

• Journal: Diabetes
• Title: Insulin-Deficient Diabetic Condition Upregulates the Insulin-Secreting Capacity of Human Induced Pluripotent Stem Cell-Derived Pancreatic Endocrine Progenitor Cells After Implantation in Mice
• Authors: Taisuke Mochida^1,3, Hikaru Ueno^1,3, Noriko Tsubooka-Yamazoe^1,3, Hideyuki Hiyoshi^1,3, Ryo Ito^1,3, Hirokazu Matsumoto^1,3, Taro Toyoda^2,3
• Author Affiliations:

1. T-CiRA Discovery, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
2. Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
3. Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, Japan